Publicacions en col·laboració amb investigadors/es de Complejo Asistencial Universitario de León (7)

2023

  1. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

    Haematologica, Vol. 108, Núm. 4, pp. 969-980

2022

  1. Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD

    Therapeutic Advances in Hematology, Vol. 13

2017

  1. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

    Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597

2015

  1. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

    Leukemia Research, Vol. 39, Núm. 1, pp. 52-57

2014

  1. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes

    Leukemia and Lymphoma, Vol. 55, Núm. 6, pp. 1300-1303

2012

  1. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

    Leukemia Research, Vol. 36, Núm. 3, pp. 287-292

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458